卫生技术评估中决策分析模型良好实践指南综述。

Review of guidelines for good practice in decision-analytic modelling in health technology assessment.

作者信息

Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, Woolacoot N, Glanville J

机构信息

Centre for Health Economics, University of York, UK.

出版信息

Health Technol Assess. 2004 Sep;8(36):iii-iv, ix-xi, 1-158. doi: 10.3310/hta8360.

Abstract

OBJECTIVES

To identify existing guidelines and develop a synthesised guideline plus accompanying checklist. In addition to provide guidance on key theoretical, methodological and practical issues and consider the implications of this research for what might be expected of future decision-analytic models.

DATA SOURCES

Electronic databases.

REVIEW METHODS

A systematic review of existing good practice guidelines was undertaken to identify and summarise guidelines currently available for assessing the quality of decision-analytic models that have been undertaken for health technology assessment. A synthesised good practice guidance and accompanying checklist was developed. Two specific methods areas in decision modelling were considered. The first method's topic is the identification of parameter estimates from published literature. Parameter searches were developed and piloted using a case-study model. The second topic relates to bias in parameter estimates; that is, how to adjust estimates of treatment effect from observational studies where there are risks of selection bias. A systematic literature review was conducted to identify those studies looking at quantification of bias in parameter estimates and the implication of this bias.

RESULTS

Fifteen studies met the inclusion criteria and were reviewed and consolidated into a single set of brief statements of good practice. From this, a checklist was developed and applied to three independent decision-analytic models. Although the checklist provided excellent guidance on some key issues for model evaluation, it was too general to pick up on the specific nuances of each model. The searches that were developed helped to identify important data for inclusion in the model. However, the quality of life searches proved to be problematic: the published search filters did not focus on those measures specific to cost-effectiveness analysis and although the strategies developed as part of this project were more successful few data were found. Of the 11 studies meeting the criteria on the effect of selection bias, five concluded that a non-randomised trial design is associated with bias and six studies found 'similar' estimates of treatment effects from observational studies or non-randomised clinical trials and randomised controlled trials (RCTs). One purpose of developing the synthesised guideline and checklist was to provide a framework for critical appraisal by the various parties involved in the health technology assessment process. First, the guideline and checklist can be used by groups that are reviewing other analysts' models and, secondly, the guideline and checklist could be used by the various analysts as they develop their models (to use it as a check on how they are developing and reporting their analyses). The Expert Advisory Group (EAG) that was convened to discuss the potential role of the guidance and checklist felt that, in general, the guidance and checklist would be a useful tool, although the checklist is not meant to be used exclusively to determine a model's quality, and so should not be used as a substitute for critical appraisal.

CONCLUSIONS

The review of current guidelines showed that although authors may provide a consistent message regarding some aspects of modelling, in other areas conflicting attributes are presented in different guidelines. In general, the checklist appears to perform well, in terms of identifying those aspects of the model that should be of particular concern to the reader. The checklist cannot, however, provide answers to the appropriateness of the model structure and structural assumptions, as these may be seen as a general problem with generic checklists and do not reflect any shortcoming with the synthesised guidance and checklist developed here. The assessment of the checklist, as well as feedback from the EAG, indicated the importance of its use in conjunction with a more general checklist or guidelines on economic evaluation. Further methods research into the following areas would be valuable: the quantification of selection bias in non-controlled studies and in controlled observational studies; the level of bias in the different non-RCT study designs; a comparison of results from RCTs with those from other non-randomised studies; assessment of the strengths and weaknesses of alternative ways to adjust for bias in a decision model; and how to prioritise searching for parameter estimates.

摘要

目的

识别现有指南并制定综合指南及配套清单。此外,就关键的理论、方法和实际问题提供指导,并考虑本研究对未来决策分析模型预期的影响。

数据来源

电子数据库。

综述方法

对现有的良好实践指南进行系统综述,以识别和总结目前可用于评估为卫生技术评估而构建的决策分析模型质量的指南。制定了综合良好实践指南及配套清单。考虑了决策建模中的两个特定方法领域。第一个方法主题是从已发表文献中识别参数估计值。使用一个案例研究模型开发并试点了参数搜索。第二个主题涉及参数估计中的偏差;即,在存在选择偏差风险的情况下,如何调整观察性研究中的治疗效果估计值。进行了系统的文献综述,以识别那些研究参数估计偏差量化及其影响的研究。

结果

15项研究符合纳入标准,经过评审并整合为一套单一的良好实践简要陈述。据此制定了一份清单,并应用于三个独立的决策分析模型。虽然该清单在模型评估的一些关键问题上提供了出色的指导,但它过于笼统,无法捕捉每个模型的具体细微差别。所开发的搜索有助于识别纳入模型的重要数据。然而,生活质量搜索被证明存在问题:已发表的搜索过滤器未聚焦于成本效益分析特有的那些指标,尽管作为本项目一部分制定的策略更成功,但找到的数据很少。在符合选择偏差影响标准的11项研究中,5项得出结论认为非随机试验设计与偏差相关,6项研究发现观察性研究或非随机临床试验与随机对照试验(RCT)的治疗效果估计值“相似”。制定综合指南和清单的一个目的是为卫生技术评估过程中涉及的各方提供批判性评估的框架。首先,该指南和清单可由审查其他分析师模型的团体使用,其次,各种分析师在开发模型时可使用该指南和清单(将其用作对他们如何开发和报告分析的检查)。为讨论该指南和清单的潜在作用而召集的专家咨询小组(EAG)认为,总体而言,该指南和清单将是一个有用的工具,尽管该清单并非专门用于确定模型的质量,因此不应用作批判性评估的替代品。

结论

对当前指南的审查表明,尽管作者在建模的某些方面可能传达了一致信息,但在其他领域,不同指南呈现出相互冲突的属性。总体而言,该清单在识别模型中读者应特别关注的那些方面似乎表现良好。然而,该清单无法为模型结构和结构假设的适当性提供答案,因为这可能被视为通用清单的一个普遍问题,并不反映此处开发的综合指南和清单的任何缺点。对该清单的评估以及EAG的反馈表明,将其与更通用的经济评估清单或指南结合使用很重要。对以下领域进行进一步的方法研究将很有价值:非对照研究和对照观察性研究中选择偏差的量化;不同非随机对照试验研究设计中的偏差程度;随机对照试验结果与其他非随机研究结果的比较;评估在决策模型中调整偏差的替代方法的优缺点;以及如何优先搜索参数估计值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索